Skip to content

Bristol Myers Squibb

Delivering Care and Support to Communities Across the UK

Overview

Our Mission

As the COVID-19 pandemic developed in the UK, Bristol Myers Squibb’s priorities became the safety of our employees and protecting and adapting the supply of key medicines to patients. We are also proud to have worked with NHS and charity partners to help those individuals and communities most impacted by the virus.

1700+

cancer patients given access to alternative treatments, under agreement with the NHS, to reduce risk to patients during the pandemic

£800,000

donated to National Emergencies Trust to support communities across the UK

Up to 6,500

extra cancer treatments a year will be delivered as a result of our support for the UK’s biggest provider of mobile cancer care

Our Response

Supporting the NHS and Vulnerable Communities

Throughout the COVID-19 pandemic, Bristol Myers Squibb (BMS) has been focused on ensuring that there is no disruption to the supply of our medicines to patients and protecting the health and safety of our workforce. We acted without hesitation to support our communities and to help the NHS maintain and recover health services.

Licensed healthcare professional colleagues are being supported as they volunteer to support the NHS on the frontline during this critical time. More widely, over 3,000 colleagues from the US, UK and Australia have registered with the BMS Skills2Give programme, to volunteer virtually with thousands of charities.

BMS has worked closely with NHS England and in the devolved nations, as well as individual NHS trusts, to help redesign health services and identify how our therapies can be delivered in alternative ways, away from hospital settings to ensure the best possible treatment outcomes.

The pandemic has highlighted the benefit of our mobile cancer care units, which increase over-stretched NHS capacity and help reduce the risk of infection by providing treatment outside of the hospital environment. As a result of Bristol Myers Squibb’s generous donation, we will be able to launch two new mobile units which will help the NHS deliver more treatment to thousands more cancer patients
Tina Seymour
Chief Executive, Hope for Tomorrow

With hospitals overwhelmed by COVID-19 patients, the NHS experienced interruptions to cancer services and treatment capacity issues due to the need for social distancing. To aid the continuation of services, BMS donated over £2 million to NHS cancer services, charities
and patient groups.

This included £747,000 for Hope for Tomorrow, the largest provider of Mobile Cancer Care Units in the UK, who are using the funds to build two new mobile units. Once the new mobile units are built and launched, our funding has the potential to expand their capacity by 30% – enabling delivery of over 6500 treatments to patients each year. These patients may otherwise have endured longer journeys, higher travel costs and growing waiting times.

Due to the national lockdowns to prevent the spread of the virus, patient organisations saw their funding streams cut overnight leaving many without the necessary funds or resources to cope with increasing demand for support from vulnerable groups. In an effort to assist with relief efforts, BMS created a COVID Emergency Fund with over £200,000 available for patient organisations, in order to help them through such a difficult period.

This support funding helped 21 patient organisations maintain capacity for their vital work, from patient support through to awareness and research.

BMS also donated £800,000 to the National Emergencies Trust coronavirus appeal in order to support this vital organisation contributing to coronavirus relief across the UK.

We are proud of the way in which BMS colleagues have responded to the COVID-19 pandemic and of their unwavering commitment to patients.

For further information on our response to COVID visit: https://www.bms.com/gb/about-us/responsibility/Our-response-to-COVID-19.html

NO-GB-2100105       April 2021

006-LVL-ChristinaCuttitta-R&D

Bristol Myers Squibb (BMS) is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, haematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.